The intrastratial injection of an adenosine A2 receptor antagonist prevents frontal cortex EEG abnormalities in a rat model of Huntington's disease

Brain Research

Volumn 831, Issue 1-2, 1999, Pages 315-318

  Reggio, Rosaria ^a   Pèzzola, Antonella ^a   Popoli, Patrizia ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Adenosine A2 receptors; EEG; Huntington's disease

Indexed keywords

3,7 DIMETHYL 1 PROPARGYLXANTHINE; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR ANTAGONIST; NEUROPROTECTIVE AGENT; QUINOLINIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; ELECTROENCEPHALOGRAM; FRONTAL CORTEX; HUNTINGTON CHOREA; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; ELECTROENCEPHALOGRAPHY; FRONTAL LOBE; HUNTINGTON DISEASE; MALE; MICROINJECTIONS; NEUROPROTECTIVE AGENTS; QUINOLINIC ACID; RATS; RATS, WISTAR; RECEPTORS, PURINERGIC P1; THEOBROMINE;

EID: 0344483876     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01489-4     Document Type: Article

References (22)

1. M.F. Beal, N.W. Kowall, D.W. Ellison, M.F. Mazurek, K.J. Swartz, U. Mac-Garvey, E.D. Bird, J.B. Martin, Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid, Nature 321 (1986) 168-171.
2. 1 receptor agonists as clinically viable agents for treatment of ischemic brain disorders, Ann. NY Acad Sci. 825 (1997) 23-29.
3. F.W. Bylsma, C.E. Peyser, S.E. Folstein, C. Ross, J. Brandt, EEG power spectra in Huntington's disease: clinical and neuropsychological correlates, Neuropsychologia 32 (1994) 137-150.
4. C. Cepeda, G.S. Colwell, J.N. Itri, E. Gruen, M.S. Levine, Dopaminergic modulation of early signs of excitotoxicity in visualized rat neostriatal neurons, Eur. J. Neurosci. 10 (1998) 3491-3497.
5. D.W. Choi, Glutamate neurotoxicity and diseases of the nervous system, Neuron 1 (1988) 623-634.
6. J.H. Connick, T.W. Stone, Quinolinic acid effects on amino acid release from the rat cerebral cortex in vitro and in vivo, Br. J. Pharmacol. 93 (1988) 868-877.
7. J.W. Daly, K.A. Jacobson, Adenosine receptors: selective agonists and antagonists, in: L. Belardinelli, A. Pelleg (Eds.), Adenosine and Adenine Nucleotides: From Molecular Biology to Integrative Physiology, Kluwer Academic Publishers, Boston, 1995, pp. 157-166.
8. M. DiFiglia, Excitotoxic injury of the neostriatum: a model for Huntington's disease, Trends Neurosci. 13 (1990) 286-289.
9. S. Ferré, B.B. Fredholm, M. Morelli, P. Popoli, K. Fuxe, Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia, Trends Neurosci. 20 (1997) 482-487.
10. 2 receptor antagonist, reduces cerebral ischemic injury in the mongolian gerbil, Life Sci. 55 (1994) PL61-65.
11. P.A. Jones, R.A. Smith, T.W. Stone, Protection against kainate-induced excitotoxicity by adenosine A2A receptor agonist and antagonists, Neuroscience 85 (1998) 229-237.
12. 2A receptor antagonist, Brain Res. 800 (1998) 328-335.
13. 2 adenosine receptor agonist CGS 21680 enhances excitatory transmitter amino acid release from the ischemic rat cerebral cortex, Neurosci. Lett. 138 (1992) 169-172.
14. T.P. Obrenovitch, J. Urenjak, Altered glutamatergic transmission in neurological disorders: from high extracellular glutamate to excessive synaptic efficacy, Progr. Neurobiol. 51 (1997) 39-87.
15. 2A receptors and neuroprotection, Ann. NY Acad. Sci. 825 (1997) 30-48.
16. P. Popoli, A. Pèzzola, M.R. Domenici, S. Sagratella, G. Diana, M.G. Caporali, E. Bronzetti, J. Vega, A. Scotti de Carolis, Behavioural and electrophysiological correlates of the quinolinic acid rat model of Huntington's disease, Brain Res. Bull. 35 (1994) 329-335.
17. 2A receptor stimulation enhances striatal extracellular glutamate levels in rats, Eur. J. Pharmacol. 287 (1995) 215-217.
18. P. Popoli, A. Pèzzola, R. Reggio, F. Tiburzi, Selective agonists of metabotropic glutamate receptors elicit significant EEG effects when infused in the nucleus accumbens of rats, European J. Pharmacol. (1999) in press.
19. M. Schwarz, F. Block, R. Topper, K.-H. Sontag, J. North, Abnormalities of somatosensory evoked potentials in the quinolinic acid model of Huntington's disease: evidence that basal ganglia modulate sensory cortical input, Ann. Neurol. 32 (1992) 358-364.
20. T.W. Scale, K.A. Abla, M.T. Shamin, J.M. Carney, J.W. Daly, 3,7-dimethyl-1-propargylxanthine: a potent and selective in vivo antagonist of adenosine analogs, Life Sci. 43 (1988) 1671-1684.
21. R.E. Simpson, M.H. O' Regan, L.M. Perkins, J.W. Phillis, Excitatory transmitter amino acid release from ischemic rat cerebral cortex: effects of adenosine receptor agonists and antagonists, J. Neurochem. 58 (1992) 1683-1690.
22. 2A receptor agonist and antagonist, Eur. J. Pharmacol. 287 (1995) 295-302.